Italian multicenter study on low-density lipoprotein apheresis: Retrospective analysis (2007)

Therapeutic Apheresis and Dialysis

Volumn 14, Issue 1, 2010, Pages 79-86

  Stefanutti, Claudia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Coronary artery disease; Dyslipidemia; Low density lipoprotein apheresis; Multicenter study

Indexed keywords

ANTICOAGULANT AGENT; HYPOCHOLESTEROLEMIC AGENT;

ADOLESCENT; ADULT; AGED; APHERESIS; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD CLOTTING; BLOOD VOLUME; CASCADE FILTRATION; CHILD; CLINICAL TRIAL; DEXTRAN SULFATE CELLULOSE ADSORPTION; DIRECT ADSORPTION OF LIPID; DYSLIPIDEMIA; FEMALE; HEALTH SURVEY; HEMATOMA; HEPARIN EXTRACORPOREAL LDL PRECIPITATION; HUMAN; IMMUNOADSORPTION; ITALY; LIPOCOLLECT 200; LOW DENSITY LIPOPROTEIN APHERESIS; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MOLECULAR GENETICS; MULTICENTER STUDY; PLASMA; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL TIME; TRANSFUSION; TREATMENT INDICATION; VASCULAR ACCESS; VEIN PUNCTURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD COMPONENT REMOVAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; ITALY; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; QUESTIONNAIRES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77149122386     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00704.x     Document Type: Article

References (32)

1. Human Genetics Programme. Familial Hypercholesterolaemia: report of a second WHO Consultation. 1999 1 42. WHO/HGN/CONS/99.2.
2. O'Neill FH, Patel DD, Knight BL et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. ATVB 2001 21 : 832 837.
3. Thompson GR, O'Neill F, Seed M. Why some patients respond poorly to statins and how this might be remedied. Eur Heart J 2002 23 : 200 206.
4. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA. Genetic determinants of statin intolerance. Lipids Health Dis 2007 6 : 7.
5. Kroon AA, Aengevaeren WR, van der Werf T et al. Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996 93 : 1826 1835.
6. Matsunaga T, Takasaki S, Masakane I, Okazaki M, Tomoike H. Changes in lipoprotein profile after selective LDL apheresis. Intern Med 2004 43 : 760.
7. Masaki N, Tatami R, Kumamoto T et al. Ten year follow up of familial hypercholesterolemia patients after intensive cholesterol lowering therapy. Int Heart 2005 46 : 833 843.
8. Geiss HC, Otto C, Hund-Wissner E, Parhofer KG. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. Atherosclerosis 2005 180 : 107 112.
9. Yamamoto A, Harada-Shiba M, Endo M et al. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis 2006 186 : 126 131.
10. Thompson GR, HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 2008 198 : 247 255.
11. Tonstad S, Thompson GR. Management of hyperlipidemia in the pediatric population. Curr Treat Options Cardiovasc Med 2004 6 : 431 437.
12. Szczepiorkowski ZM, Bandarenko N, Kim HC. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007 22 : 106 175.
13. Bosch T, Gahr S, Belschner U et al. Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: results of a prospective long-term multicenter follow-up covering 12,291 sessions. Ther Apher Dial 2006 10 : 210 218.
14. Kanemitsu S, Takekoshi N, Matsui S et al. Short term and long term effects of low density lipoprotein apheresis on restenosis after PTCA: is lowering Lp(a) by LDL apheresis effective on restenosis after PTCA? Ther Apher 1998 2 : 65 70.
15. Kfoury-Baz EM, Nassar RA, Tanios RF et al. Plasmapheresis in asparaginase-induced hypertriglyceridemia. Transfusion 2008 48 : 1227 1230.
16. Grundy SM, Cleeman JI, Bairey Merz CN et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004 110 : 227 239.
17. Matsuzaki M, Hiramori K, Imaizumi T et al. Intravascular sound evaluation of coronary plaque regression by low density lipoprotein apheresis in familial hypercholesterolemia: The Low Density Lipoprotein Apheresis Coronary Morphology and Reserved Trial (LACMART). J Am Coll Cardiol 2002 40 : 220 227.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 2497.
19. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein (a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 2003 49 : 1785 1796.
20. Schettler V, Wieland E, Armstrong VW et al. First steps toward the establishment of a German LDL-apheresis registry: recommendations for the indication and for quality management. Ther Apher 2002 6 : 381 383.
21. Tasaki H, Yamashita K, Saito Y et al. Low-density lipoprotein apheresis therapy with a direct hemoperfusion column: a Japanese multicenter clinical trial. Ther Apher Dial 2006 10 : 32 41.
22. Stefanutti C, Di Giacomo S, Mazzarella B, Castelli A. LDL-apheresis: a novel technique (LIPOCOLLECT 200 ®). Artif Organs 2009 (in press).
23. Palcoux JB, Atassi-Dumont M, Lefevre P et al. Lipoprotein Apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial 2008 12 : 195 201.
24. Korach JM, Guillevin L, Petitpas D, Berger P, Chillet P. Apheresis registry in France: indications, techniques and complications. French Registry Study Group. Ther Apher 2000 4 : 207 210.
25. Norda R, Stegmayr BG. Swedish Apheresis Study Group Apheresis Registry in Sweden: scope, techniques, and indications for treatment. A report from the Swedish apheresis study group. Transfus Apher Sci 2001 24 : 49 55.
26. Stegmayr BG, Guillevin L, Korach JM, Rock G, Norda R, Ramlow W. The role of an international apheresis registry for the establishment of apheresis therapy. Ther Apher Dial 2005 9 : A37 A37.
27. Stegmayr B, Ptak J, Wikström B et al. World apheresis registry: report of 2004 data. Ther Apher Dial 2005 9 : A38 A38.
28. Malchesky PS, Koo AP, Roberson GA, Hadsell AT, Rybicki LA. Apheresis technologies and clinical applications: the 2005 International Apheresis Registry. Ther Apher Dial 2007 11 : 341 362.
29. De Silvestro G, Marson P, Russo GE, Vicarioto M, Donadel C. National survey of apheresis activity in Italy (2000). Transfus Apher Sci 2004 30 : 61 71.
30. Passalacqua S, Staffolani E, Busnach G et al. The Italian Registry for Therapeutic Apheresis. A report from the Apheresis Study Group of the Italian Society of Nephrology. J Clin Apher 2005 20 : 101 106.
31. De Silvestro G, Tison T, Vicariato M, Bagattella P, Stefanutti C, Marson P. The Italian Registry of Pediatric Therapeutic Apheresis: a report on activity during 2005. J Clin Apher 2009 24 : 1 5.
32. Valenti B, de Varennes M, Marcil C et al. Vascular Calcifications in Homozygote Familial Hypercholesterolemia. Arterioscler Thromb Vasc Biol 2008 28 : 777 785.